Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Tazverik
Tazemetostat is an inhibitor of the histone methyltransferase EZH2, an enzyme that plays a role in gene regulation and is often overexpressed in certain cancers. It is used to treat adults and pediatric patients (6 years and older) with epithelioid sarcoma not eligible for complete resection and adults with follicular lymphoma whose cancer has come back after two or more prior systemic therapies. It interferes with EZH2 function, leading to changes in gene expression and suppression of cancer cell growth.
Tazemetostat is used to treat certain types of sarcoma and follicular lymphoma.
Outcome:
Decreased tazemetostat levels
Mechanism:
Increased metabolism
Outcome:
Decreased tazemetostat levels
Mechanism:
Increased metabolism
Outcome:
May slightly increase tazemetostat absorption
Mechanism:
Enhanced solubility
Most likely new formulation: Extended-release formulation (Year: 2026, 70% confidence)
Based on clinical trial data and current usage trends, there is a high likelihood (>80%) that tazemetostat will remain a key treatment option for specific subtypes of sarcoma and lymphoma.
Antineoplastic Agent, Histone Methyltransferase Inhibitor
Pyridinone